Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Interleukin-6, a new target for therapy in multiple myeloma?

Literature DB >> 8507716

Interleukin-6, a new target for therapy in multiple myeloma?

M H van Oers¹, H C van Zaanen, H M Lokhorst.

Abstract

During the past few years much insight has been gained into the immunobiology of multiple myeloma. It has become evident that the growth of myeloma cells is regulated by cytokines, notably interleukin-6. In this paper a brief review is given of the evidence derived from in vitro as well as in vivo observations that interleukin-6 is involved in the pathogenesis of multiple myeloma, and the implications of these findings for the development of new therapeutic strategies are discussed.

Entities: Disease Gene

Mesh：

Substances：

Year: 1993 PMID： 8507716 DOI： 10.1007/BF01738469

Source DB: PubMed Journal: Ann Hematol ISSN： 0939-5555 Impact factor: 3.673

54 in total

1. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells.

Authors: X G Zhang; R Bataille; M Jourdan; S Saeland; J Banchereau; P Mannoni; B Klein
Journal: Blood Date: 1990-12-15 Impact factor: 22.113

2. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

Authors: X G Zhang; B Klein; R Bataille
Journal: Blood Date: 1989-07 Impact factor: 22.113

3. Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop.

Authors: H Jernberg-Wiklund; M Pettersson; M Carlsson; K Nilsson
Journal: Leukemia Date: 1992-04 Impact factor: 11.528

4. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma.

Authors: M Portier; G Rajzbaum; X G Zhang; M Attal; C Rusalen; J Wijdenes; P Mannoni; D Maraninchi; M Piechaczyk; R Bataille
Journal: Eur J Immunol Date: 1991-07 Impact factor: 5.532

5. Interleukin-6 enhances human Ig production, but not as a terminal differentiation factor for B lymphocytes.

Authors: C Van Kooten; M H Van Oers; L A Aarden
Journal: Res Immunol Date: 1990 May-Jun

6. Multiple myeloma treated with high dose intravenous melphalan.

Authors: P J Selby; T J McElwain; A C Nandi; T J Perren; R L Powles; C R Tillyer; R J Osborne; M L Slevin; J S Malpas
Journal: Br J Haematol Date: 1987-05 Impact factor: 6.998

7. Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1.

Authors: R P Nordan; J G Pumphrey; S Rudikoff
Journal: J Immunol Date: 1987-08-01 Impact factor: 5.422

8. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors: T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal: Nature Date: 1986 Nov 6-12 Impact factor: 49.962

9. Growth autonomy and tumorigenicity of interleukin 6-dependent B cells transfected with interleukin 6 cDNA.

Authors: N Tohyama; H Karasuyama; T Tada
Journal: J Exp Med Date: 1990-02-01 Impact factor: 14.307

10. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.

Authors: L Bergui; M Schena; G Gaidano; M Riva; F Caligaris-Cappio
Journal: J Exp Med Date: 1989-08-01 Impact factor: 14.307

5 in total

1. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.

Authors: H C van Zaanen; R P Koopmans; L A Aarden; H J Rensink; J M Stouthard; S O Warnaar; H M Lokhorst; M H van Oers
Journal: J Clin Invest Date: 1996-09-15 Impact factor: 14.808